Multiple sclerosis diagnosis and phenotype identification by multivariate classification of in vivo frontal cortex metabolite profiles
Swanberg, Kelley M LU
; Kurada, Abhinav V
; Prinsen, Hetty
and Juchem, Christoph
(2022)
In Scientific Reports
12(1).
- Abstract
Multiple sclerosis (MS) is a heterogeneous autoimmune disease for which diagnosis continues to rely on subjective clinical judgment over a battery of tests. Proton magnetic resonance spectroscopy (1H MRS) enables the noninvasive in vivo detection of multiple small-molecule metabolites and is therefore in principle a promising means of gathering information sufficient for multiple sclerosis diagnosis and subtype classification. Here we show that supervised classification using 1H-MRS-visible normal-appearing frontal cortex small-molecule metabolites alone can indeed differentiate individuals with progressive MS from control (held-out validation sensitivity 79% and specificity 68%), as well as between relapsing and progressive MS... (More)
Multiple sclerosis (MS) is a heterogeneous autoimmune disease for which diagnosis continues to rely on subjective clinical judgment over a battery of tests. Proton magnetic resonance spectroscopy (1H MRS) enables the noninvasive in vivo detection of multiple small-molecule metabolites and is therefore in principle a promising means of gathering information sufficient for multiple sclerosis diagnosis and subtype classification. Here we show that supervised classification using 1H-MRS-visible normal-appearing frontal cortex small-molecule metabolites alone can indeed differentiate individuals with progressive MS from control (held-out validation sensitivity 79% and specificity 68%), as well as between relapsing and progressive MS phenotypes (held-out validation sensitivity 84% and specificity 74%). Post hoc assessment demonstrated the disproportionate contributions of glutamate and glutamine to identifying MS status and phenotype, respectively. Our finding establishes 1H MRS as a viable means of characterizing progressive multiple sclerosis disease status and paves the way for continued refinement of this method as an auxiliary or mainstay of multiple sclerosis diagnostics.
(Less)
- author
- Swanberg, Kelley M
LU
; Kurada, Abhinav V
; Prinsen, Hetty
and Juchem, Christoph
- publishing date
- 2022-08-16
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Frontal Lobe/metabolism, Humans, Magnetic Resonance Spectroscopy/methods, Multiple Sclerosis/diagnostic imaging, Multiple Sclerosis, Chronic Progressive/metabolism, Phenotype
- in
- Scientific Reports
- volume
- 12
- issue
- 1
- article number
- 13888
- publisher
- Nature Publishing Group
- external identifiers
-
- scopus:85136040443
- pmid:35974117
- ISSN
- 2045-2322
- DOI
- 10.1038/s41598-022-17741-8
- language
- English
- LU publication?
- no
- additional info
- © 2022. The Author(s).
- id
- 72abff6d-87ed-4631-842a-f31651b4ece4
- date added to LUP
- 2023-09-18 14:59:25
- date last changed
- 2024-04-19 01:21:13
@article{72abff6d-87ed-4631-842a-f31651b4ece4,
abstract = {{<p>Multiple sclerosis (MS) is a heterogeneous autoimmune disease for which diagnosis continues to rely on subjective clinical judgment over a battery of tests. Proton magnetic resonance spectroscopy (1H MRS) enables the noninvasive in vivo detection of multiple small-molecule metabolites and is therefore in principle a promising means of gathering information sufficient for multiple sclerosis diagnosis and subtype classification. Here we show that supervised classification using 1H-MRS-visible normal-appearing frontal cortex small-molecule metabolites alone can indeed differentiate individuals with progressive MS from control (held-out validation sensitivity 79% and specificity 68%), as well as between relapsing and progressive MS phenotypes (held-out validation sensitivity 84% and specificity 74%). Post hoc assessment demonstrated the disproportionate contributions of glutamate and glutamine to identifying MS status and phenotype, respectively. Our finding establishes 1H MRS as a viable means of characterizing progressive multiple sclerosis disease status and paves the way for continued refinement of this method as an auxiliary or mainstay of multiple sclerosis diagnostics.</p>}},
author = {{Swanberg, Kelley M and Kurada, Abhinav V and Prinsen, Hetty and Juchem, Christoph}},
issn = {{2045-2322}},
keywords = {{Frontal Lobe/metabolism; Humans; Magnetic Resonance Spectroscopy/methods; Multiple Sclerosis/diagnostic imaging; Multiple Sclerosis, Chronic Progressive/metabolism; Phenotype}},
language = {{eng}},
month = {{08}},
number = {{1}},
publisher = {{Nature Publishing Group}},
series = {{Scientific Reports}},
title = {{Multiple sclerosis diagnosis and phenotype identification by multivariate classification of in vivo frontal cortex metabolite profiles}},
url = {{http://dx.doi.org/10.1038/s41598-022-17741-8}},
doi = {{10.1038/s41598-022-17741-8}},
volume = {{12}},
year = {{2022}},
}